Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 60, Issue 12, 2013, Pages 2073-2078

  Johnston, Donna L ^a   Alonzo, Todd A ^b   Gerbing, Robert B ^c   Hirsch, Betsy ^d   Heerema, Nyla A ^e   Ravindranath, Yaddanapudi ^f   Woods, William G ^g   Lange, Beverly J ^h   Gamis, Alan S ⁱ   Raimondi, Susana C ^j  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^g EMORY UNIVERSITY   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ CHILDREN S MERCY HOSPITAL   (United States)

^j ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

5 5q abnormalities; Acute myeloid leukemia; Chromosome 5; Outcome; Pediatric AML

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 5Q; CHROMOSOME 5Q ABNORMALITY; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INFANT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NEWBORN; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL TIME;

-5/5Q- ABNORMALITIES; ACUTE MYELOID LEUKEMIA; CHROMOSOME 5; OUTCOME; PEDIATRIC AML;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 5; DISEASE-FREE SURVIVAL; FEMALE; GENE DELETION; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885727057     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24573     Document Type: Article

References (26)

1. Patnaik MM, Lasho TL, Finke CM, et al. Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients. Am J Hematol 2011; 86:393-398.
2. Visani G, Bernasconi P, Boni M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia-Analysis of 848 patients. Leukemia 2001; 15:903-909.
3. Middeke JM, Beelen D, Stadler M, et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation; negative impact of abnl(17p) and -5/5q-. Blood 2012; 120:2521-2528.
4. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. J Clin Oncol 2010; 28:2674-2681.
5. Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and deletion 7q in children and adolescents with a cute myeloid leukemia: An international retrospective study. Blood 2007; 109:4641-4647.
6. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 1996; 87:4979-4989.
7. Ravindranath Y, Yeager AM, Chang M, et al. Autologous bone marrow transplantation vs. intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334:1428-1434.
8. Becton D, Dahl G, Ravindranath Y, et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group study 9421 Blood 2006; 107:1315-1324.
9. Lange B, Smith FO, Feusner J, et al. Outcomes in CCG-2961, A Children's Oncology Group Phase 3 trial for untreated pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group. Blood 2008; 111:1044-1053.
10. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzamab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia. Cancer 2012; 118:761-769.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
12. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, New York: Wiley John, and Sons, Inc.; 1980.
13. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-1154.
14. Shaffer LG, Slovak ML, Campbell LJ. editors. An international system for human chromosome nomenclature. Basel: S. Karger; 2009.
15. Amadori S, Venditti A, Del Poeta G, et al. Minimally differentiated acute myeloid leukemia (AML-M0): A distinct clinico-biologic entity with poor prognosis. Ann Hematol 1996; 72:208-215.
16. Bene MC, Bernier M, Casasnovas RO, et al. Acute myeloid leukaemia M0: Haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: An analysis in 241 patients. Br J Haematol 2001; 113:737-745.
17. Creutzig U, Harbott J, Sperling C, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87. Blood 1995; 86:3097-3108.
18. Stasi R, Del Poeta G, Venditti A, et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood 1994; 83:1619-1625.
19. Cuneo A, Ferrant A, Michaux JL, et al. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: Correlation with clinicobiologic findings. Blood 1995; 85:3688-3694.
20. Barbaric D, Alonzo TA, Gerbing RB, et al. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: A report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. Blood 2007; 109:2314-2321.
21. Silva FPG, Almeida I, Morolli B, et al. Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. Haematologica 2009; 94:1546-1554.
22. Kayser S, Zucknick M, Dohner K, et al. Monosomal karyotype in adult acute myeloid leukemia: Prognostic impact and outcome after different treatment strategies. Blood 2012; 119:551-558.
23. Breems DA, van Putten WL, De Greef GE, et al. Monsomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791-4797.
24. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype and dismal outcome. Blood 2012; 119:2114-2121.
25. Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009; 115:5746-5751.
26. Chen Y, Kantarjian H, Estrov Z, et al. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk 2012; 12:341-344.